But, for many patients this therapy isn’t enough. And stepping back you realize that we have been driving these CAR-T cells with the same basic design for the last 15 years,” Kohler said. “When we ...
Despite its promise, autologous chimeric antigen receptor T-cell (CAR T-cell) therapy faces several challenges, including limited accessibility, high costs and manufacturing bottlenecks. Allogeneic ...
New CAR-T cell therapy shows promise for hard-to-treat cancers Date: March 10, 2025 Source: University of Colorado Anschutz Medical Campus Summary: Researchers have successfully developed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback